
TSE:MFC
This summary was created by AI, based on 27 opinions in the last 12 months.
Manulife Financial (MFC) has garnered mixed perspectives from various analysts, reflecting both its potential and current market position. While many experts acknowledge MFC's solid dividend yield and growth prospects, particularly in Asia, concerns about valuation and market conditions persist. The stock appears to be trading around 2x book value and has shown slow but steady growth, attracting attention from those looking for income rather than explosive growth. The consensus among experts is to proceed with caution and consider market pullbacks for optimal entry points, though some view the stock as a good long-term hold due to its stable dividend and cash flow. Overall, while there are positive signs, such as asset management improvements and capital growth, analysts advise careful monitoring given the mixed signals surrounding the broader financial sector's performance.
In a low interest rate environment, it is very difficult for lifecos to make money. Auditors at some point are going to look at the reinvestment rate required, and there is speculation they may actually lower it, meaning the company has to hold more cash on its balance sheet. However, the franchise value is excellent. Great wealth management business. Growing hand over fist in Asia. If they can just overcome the negative sentiment as it pertains to interest rates and maybe start to take a longer term time horizon into 2017-2018, then you can make a case for it.
The difficulty with the lifecos is that the longer it takes for them to normalize interest rates, the tougher it is going to be on them. They have obligations that go 20 years in the future, and have to do an offset. When we go to a more normalized yield curve, that is a bonus to the lifecos. He is starting to lose patience, and might put this one on the boat if rates don’t improve.
A well-run company and well diversified in Canada and the US, as well as Asia. The issue for all insurance companies right now is the very low interest rate. Thinks interest rates will gradually move up over the next few years and their operation will get better. Long-term it is still a good buy, but shorter term you are probably not going to see a lot of upside.
Share price has been disappointing for the last 1-1.5 years. They’ve had headwinds with the energy sector and their bond and loan portfolios. Resolved their problems from the financial crisis and are on mode now to invest and to grow. Hopefully the macro headwinds are now largely behind them. Stock was punished because they missed expectations, so valuations are now quite attractive at about 1X BV. Likes their exposure to the Asian market. She would start buying here on a pullback.
This has frustrated many, many people for the better part of 10 years. They disappointed in the latest quarter with some of their numbers, and they keep writing down assets. They had quite a bit of exposure to oil/gas which hurt them. It is probably going to sit in the $17-$19 range. He is not interested in it.
(A Top Pick Nov 5/15. Down 10.79%.) Bought this for a highly visible EPS growth, high dividend growth and a lower Cdn$ because they have some operations outside of Canada. All of this transpired. Unfortunately, their energy book brought down their book value per share. Also, low interest rate hurt the whole sector. He still models an 11% EPS growth, each year, for the next couple of years, and an 11% dividend growth. Trading at 10.2 versus its peers at 11. The whole lifecos sector is cheaper than the banks. This name can still work.